The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...

Pfizer Inc. (NYSE:PFE) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider of Goldman ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Lynozyfic’s global sales are projected to reach $707 million by 2031.